Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

Anti-angiogenic agents and immunotherapy are the cornerstone of advanced/metastatic renal-cell carcinoma (mRCC) treatment. Recently, the therapeutic scenario of first-line therapy for mRCC has been completely revolutionized. The combination of the two immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab (targeting PD-1 and CTLA4, respectively) yielded a significant survival advantage, compared to sunitinib, in International Metastatic RCC Database consortium (IMDC) intermediate- and poor-risk patients, but failed to improve outcomes of favorable-risk patients [1].

Source: Cancer Treatment Reviews - September 18, 2021 Category: Cancer & Oncology Authors: C. Ciccarese, R. Iacovelli, C. Porta, G. Procopio, E. Bria, S. Astore, MA. Cannella, G. Tortora Source Type: research